health

FDA approves Eli Lilly’s Trulicity to reduce cardiovascular risks in type 2 diabetic patients

Eli Lilly and Co said  the U.S. Food and Drug Administration has approved Trulicity for reducing cardiovascular risk factors in type 2 diabetic patients.

The approval makes Trulicity the first and only type 2 diabetes drug approved to reduce heart related risks in adults with and without established cardiovascular disease, the company said in a statement.

http://international-journal.com/

 

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

− 2 = 1

Close